Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Holista Colltech Limited ( (AU:HCT) ) just unveiled an update.
Holista Colltech reported quarterly revenue of about $1.49 million for the period ended 31 March 2026, with approximately $1.47 million contributed by its core supplements segment, underscoring resilient customer demand. Smaller contributions came from the food ingredients and infection control/agriculture divisions, while the ovine collagen segment saw no revenue due to timing of supply and fulfilment.
The company posted cash receipts of roughly $1.31 million against operating payments of about $1.47 million, resulting in a net operating cash outflow driven by inventory build-up and one-off legal costs. Management also recorded modest investing and financing outflows and advanced settlement of the ProImmune legal matter, signalling a focus on stabilising operations and resolving legacy issues despite tight cash conditions.
More about Holista Colltech Limited
Holista Colltech Limited is an ASX-listed health and wellness company that generates most of its revenue from its supplements division. The group also operates smaller food ingredients, ovine collagen, and infection control/agriculture segments, targeting consumer health markets and specialised industrial applications.
Average Trading Volume: 45,723
Technical Sentiment Signal: Sell
Current Market Cap: A$18.76M
For an in-depth examination of HCT stock, go to TipRanks’ Overview page.